Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

FDA Approves Ibrutinib Plus Rituximab for Chronic Lymphocytic Leukaemia

Approval is based on the results from the E1912 trial
27 Apr 2020
Anticancer agents & Biologic therapy;  Haematologic malignancies

On 21 April 2020, the US Food and Drug Administration (FDA) expanded the indication of ibrutinib (IMBRUVICA, Pharmacyclics LLC) to include its combination with rituximab for the initial treatment of adult patients with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL).

This review was conducted under Project Orbis, an initiative of the FDA Oncology Center of Excellence (OCE). Project Orbis provides a framework for concurrent submission and review of oncology drugs among international partners. For this application, a modified Project Orbis was undertaken because of the timing of submission to other regulatory agencies. Nevertheless, the FDA is collaborating with the Australian Therapeutic Goods Administration, Health Canada, and Swissmedic as they review the application.

Approval was based on the E1912 trial (NCT02048813), a 2:1 randomised, multicentre, open-label, actively controlled trial of ibrutinib with rituximab compared to fludarabine, cyclophosphamide, and rituximab (FCR) in 529 adult patients 70 years or younger with previously untreated CLL or SLL requiring systemic therapy. Patients with 17p deletion were excluded. Ibrutinib was administered at 420 mg daily until disease progression or unacceptable toxicity. 

The main efficacy outcome measure was progression-free survival (PFS). The trial demonstrated a statistically significant improvement in PFS for patients receiving ibrutinib plus rituximab compared with those receiving FCR (hazard ratio 0.34; 95% confidence interval 0.22, 0.52; p < 0.0001). Median PFS was not reached in either arm after a median follow-up duration of 37 months.

The most common adverse reactions (≥30%) in patients with CLL/SLL receiving ibrutinib are thrombocytopenia, diarrhoea, fatigue, musculoskeletal pain, neutropenia, rash, anaemia, bruising, and nausea.

The recommended ibrutinib dose is 420 mg taken orally once daily with a glass of water. Rituximab was initiated in cycle 2 and administered at 50 mg/m2 on day 1, 325 mg/m2 on day 2, and 500 mg/m2 on day 1 of 5 subsequent cycles, for a total of 6 cycles.

Full prescribing information for IMBRUVICA is available here.

FDA used the Real-Time Oncology Review and Assessment Aid Pilot Programmes for this application and the application was granted priority review. The Assessment Aid is being used to facilitate discussions among the regulatory agencies participating in Project Orbis.

Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System.

For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact OCE’s Project Facilitate.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings